Comparison of the clinical effect of prednisone slow reduction in the treatment of autoimmune hepatitis

Abstract

Abstract: Objective To investigate the clinical effect of slow reduction of prednisone in the treatment of autoimmune hepatitis.Methods 86 patients with autoimmune hepatitis were randomly divided into fast group and slow group, with 43 cases in each group. The therapeutic effect, liver function indexes and adverse reactions were compared between the two groups. Results The effective rate of slow group was significantly higher than that of fast group (P<0.05). The index of liver function in slow group was significantly better than that in fast group (P < 0.05). There was no significant difference between two groups (P>0.05).Conclusion The clinical effect of prednisone slow reduction in the treatment of autoimmune hepatitis was better and the adverse reactions were not increased.

Key words: Autoimmune hepatitis, Prednisone, Dose, Efficacy

TIAN Xiao-ling, CHEN Li, LU Ying-jia, HE Yao. Comparison of the clinical effect of prednisone slow reduction in the treatment of autoimmune hepatitis[J]. Chinese Hepatolgy, 2021, 26(5): 547-549.

References

[1] Tanaka A, Mori M, Matsumoto K, et al. An increase trend in the prevalence and male-to-female ratio of primary biliary cholangitis, autoimmune hepatitis, and primary sclerosing cholangitis in Japan. Hepatol Res, 2019,19:133-135.
[2] Valgeirsson KB, Hreinsson JP, Bjrnsson ES. Increased incidence of autoimmune hepatitis is associated with wider use of biological drugs. Liver Int, 2019, 39:193-199.
[3] Lauri, Puustinen, Nina, et al. Incidence, prevalence, and causes of death of patients with autoimmune hepatitis: A nationwide register-based cohort study in Finland. Dig Liver Dis, 2019, 51:1294-1299.
[4] de Moraes Falco LT, Terrabuio DRB, Diniz MA, et al. Efficacy and safety of chloroquine plus prednisone for the treatment of autoimmune hepatitis in a randomized trial. JGH Open, 2019, 4:371-377.
[5] Chapman RW, Aspinall RJ, Trivedi P, et al. Challenges in the use of corticosteroids in the management of autoimmune hepatitis. Br J Hosp Med (Lond), 2019, 80:594-599.
[6] A, J, Czaja. Emerging Treatments for Autoimmune Hepatitis. C Targets Inflamm Allergy, 2002, 38: 150-155.
[7] Brand FVD, Boer YD, Nieuwkerk KV, et al. FRI-063-Low-dose prednisone increases the risk of adverse events in autoimmune hepatitis patients. J Hepatology, 2019, 70:e413.
[8] Llovet LP, Horta D, Eliz MG, et al. Pregnancy and autoimmune hepatitis: presentation and outcomes. J Hepatology, 2018, 68:S233.
[9] Prasad D, Poddar U, Kanaujia V, et al. Effect of Long-term Oral Steroids on Intraocular Pressure in Children With Autoimmune Hepatitis: a Prospective Cohort Study. J Glaucoma, 2019, 28:492-495.
[10] Ashnila J, Hirschfield GM. Autoimmune hepatitis and complexities in management. Frontline Gastroenterol, 2018, 10:77-87.
[11] Soloway RD, Summerskill WH, Baggenstoss AH, et al. Clinical, biochemical, and histological remission of severe chronic active liver disease: a controlled study of treatments and early prognosis.Gastroenterology, 1972,63:820-833.
[12] Murray-Lyon IM, Stern RB, Williams R. Controlled trial of prednisone and azathioprine in active chronic hepatitis.Lancet, 1973,1:735-737.
[13] Lamers MM, van Oijen MG, Pronk M, Drenth JP. Treatment options for autoimmune hepatitis: a systematic review of randomized controlled trials. J Hepatol, 2010, 53:191-198.
[14] Purnak T, Efe C, Kav T, et al. Treatment Response and Outcome with Two Different Prednisolone Regimens in Autoimmune Hepatitis. Dig Dis Sci, 2017, 12: 193-195.
[15] Swann J W, Szladovits B, Threlfall A J, et al. Randomised controlled trial of fractionated and unfractionated prednisolone regimens for dogs with immune-mediated haemolytic anaemia. Vet Rec, 2019, 184:vetrec-2018-105104.